Vaxart Reports 12-Month Safety Data Showing No SAEs

Vaxart reported top-line safety data for its Phase 2b oral COVID-19 vaccine, finding no vaccine-related serious adverse events or sustained Grade 3 adverse events. This positive result supports the oral pill candidate's development profile as efficacy data is still pending.